Foundational guide
FOXO4-DRI Peptide Cycle: A Category Error, Examined
Cycling presumes a compound whose effect tracks its presence. A senolytic removes a population and stops, which is a different pharmacological shape entirely.
A FOXO4-DRI peptide cycle applies vocabulary from continuous-exposure pharmacology to a compound whose mechanism is elimination rather than maintenance. The mismatch is not semantic; it changes what a schedule would even be for.
There is also no human schedule at any length, because no human has received the compound in a registered trial.
Supplier publishing lot-level data
FOXO4-DRI, Ascension Peptides
Two independent laboratories have certified this product, though on different batches. The code below halves the listed price on the vial.
The two published certificates cover different lots and disagree on fill: Kovera Labs assays batch 55-05260628 at 11.41 mg, MZ Biolabs assays lot 55-01260229 at 8.30 mg, both against a 10 mg label, moving the real figure between $5.87/mg and $8.07/mg. Endotoxin and sterility screens appear on the Kovera lot only, so testing scope here is a batch property rather than a product feature. The vendor spells the product FOX04 with a zero, including in the link.
- Kovera Labs and MZ Biolabs certificates, different lots
- Carriage free above $250
- Same-day dispatch before 2pm CST
Laboratory research material only, not for human consumption. FOXO4-DRI holds no marketing authorisation in any market and has never been administered in a registered human trial. Affiliate links: we may earn a commission at no additional cost to you. Figures checked September 2, 2026.
Two pharmacological shapes
Cycling logic assumes that effect tracks presence: occupy a receptor, sustain a signal, accumulate adaptation, then withdraw and allow recovery. Duration is the operative variable because exposure is the mechanism.
Senolytic logic inverts this. The compound eliminates a cell population, after which there is nothing further to act upon until that population re-accumulates, a process measured in months and years. Exposure beyond clearance adds risk without benefit.
| Dimension | Continuous exposure | Clearance |
|---|---|---|
| Effect tracks | Plasma concentration | Population removed |
| Duration | Weeks, by design | Three doses across five days |
| On cessation | Effect decays | Effect persists until re-accumulation |
| Reason to stop | Suppression, tolerance | Nothing left to act on |
| Recovery phase | Frequently required | Nothing to recover |
The published schedule
In the 2017 study, mice received FOXO4-DRI at 5 mg/kg on days 1, 3 and 5, intravenously in the chemotoxicity arm and intraperitoneally in the ageing arms. Doxorubicin, used to induce senescence, was administered separately at 10 mg/kg.
Three administrations, then nothing. That is the entirety of the published schedule and it is an experimental parameter within a mouse model rather than a template for anything.
Body-weight scaling from that figure produces a number without validation. Allometric scaling estimates a starting point for formal study and requires pharmacokinetic inputs, none of which has been measured for this peptide in humans.
Not an anabolic compound
The cycle framing typically arrives from performance pharmacology, so the boundary is worth stating explicitly.
FOXO4-DRI does not bind androgen receptors, does not stimulate growth hormone secretion, does not influence protein synthesis, and has not been evaluated against any muscle, strength or performance endpoint in any species. There is no null result to cite because the experiment has not been run.
The mechanistic connection to ageing tissue is indirect: senescent cells accumulate in ageing tissue and their secretory profile is implicated in declining repair capacity. That is a maintenance hypothesis with preclinical support in other tissues, not a performance claim.
What is not provided here
No cycle length, no stacking combinations, no schedule for human use. These are absent because no evidence supports any of them, not because they are being withheld.
FOXO4-DRI holds no approval from the FDA, the EMA or the MHRA, and ClinicalTrials.gov lists no registered interventional study in humans. There is no established dose, no measured half-life, no tolerability data and no adverse-event record.
A 2023 report additionally found that eliminating senescent cells could promote pulmonary hypertension development and progression, so the expected direction of effect is not settled even at the level of strategy.
Frequently asked questions
- How long should a FOXO4-DRI cycle be?
- No human schedule of any length has been established. The animal work used three administrations across five days in mice, which is an experimental parameter rather than a template.
- Is FOXO4-DRI anabolic?
- No. It has no anabolic mechanism and has never been evaluated against a muscle, strength or performance endpoint in any species.
- Why was the animal schedule so short?
- Because a senolytic clears a cell population rather than sustaining a signal. After clearance there is nothing to act on until cells re-accumulate, which takes months to years.
- Is post-cycle support relevant?
- No. Post-cycle protocols address suppression caused by compounds acting on hormonal axes. FOXO4-DRI does not act on those axes and suppresses nothing.
Limitations of the evidence
No human dosing schedule exists for FOXO4-DRI and none is provided here. The animal schedule described is an experimental parameter within a specific model, not a template. No stacking, duration or recovery guidance is given because no evidence supports any.
References
Citations are annotated with an evidence tier reflecting study design and replication. See Methodology for criteria.
- 1.Baar MP, Brandt RMC, Putavet DA, et al. · Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging · Cell · 2017PMID 28340339Preclinical
- 2.Bourgeois B, Spreitzer E, Platero-Rochart D, et al. · The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI · Nature Communications · 2025PMID 40593617Preclinical
- 3.Circulation · Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression · Circulation · 2023PMID 36515093Preclinical